Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSICA SCHROEDER

Allopathic & Osteopathic Physicians Pediatrics

NPI
1851438733
CMS profile
265156
Location
WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$38.13

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $38.13 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $20.15 1
CooperSurgical, Inc. $17.98 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSICA SCHROEDER

NPI 1851438733 · CMS profile ID 265156

Allopathic & Osteopathic Physicians / Pediatrics

WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851438733?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSICA SCHROEDER, NPI 1851438733, CMS profile ID 265156. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851438733?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JESSICA SCHROEDER, NPI 1851438733, CMS profile ID 265156. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851438733?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JESSICA SCHROEDER, NPI 1851438733, CMS profile ID 265156, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1851438733?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $38.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI PASTEUR INC. $20.1506/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691584971 CMS
CooperSurgical, Inc. $17.9805/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693963545 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $38.13 2
PY2021 $16.13 1
PY2023 $110.87 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $117,691.97 38
PY2024 Principal investigator $40,947.23 25
PY2023 Principal investigator $55,569.24 24
PY2022 Principal investigator $59,927.56 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
3110-305-002 Ph3 Pivotal Peds Post Approval - PMR (M21-265) No dispute reported 06/30/2026 1100766963
Principal investigator 1 ABBVIE INC. $5,712.64 12/30/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100763504
Principal investigator 1 ABBVIE INC. $3,244.65 11/06/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100751851
Principal investigator 1 ABBVIE INC. $2,655.97 11/06/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100751853
Principal investigator 1 ABBVIE INC. $18.23 10/22/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100749572
Principal investigator 1 ABBVIE INC. $1,193.40 10/03/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100745402
Principal investigator 1 ABBVIE INC. $692.76 10/03/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100745406
Principal investigator 1 ABBVIE INC. $2,301.75 09/03/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100738758
Principal investigator 1 ABBVIE INC. $350.00 08/29/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100738028
Principal investigator 1 ABBVIE INC. $309.49 08/01/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100732484
Principal investigator 1 ABBVIE INC. $1,193.40 08/01/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100732530
Principal investigator 1 ABBVIE INC. $4,461.75 07/03/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100725394
Principal investigator 1 ABBVIE INC. $103.46 06/20/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100724084
Principal investigator 1 ABBVIE INC. $928.47 06/06/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100721910
Principal investigator 1 ABBVIE INC. $4,461.75 05/08/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100716974
Principal investigator 1 ABBVIE INC. $92.80 04/24/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100714902
Principal investigator 1 ABBVIE INC. $109.15 04/24/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100714908
Principal investigator 1 ABBVIE INC. $3,298.05 04/04/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100713026
Principal investigator 1 ABBVIE INC. $300.00 04/04/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100713028
Principal investigator 1 ABBVIE INC. $300.00 04/04/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100713072
Principal investigator 1 ABBVIE INC. $300.00 04/04/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100713074
Principal investigator 1 ABBVIE INC. $300.00 02/20/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100704212
Principal investigator 1 ABBVIE INC. $692.76 02/01/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100702258
Principal investigator 1 ABBVIE INC. $4,179.60 02/01/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100702326
Principal investigator 1 ABBVIE INC. $2,307.15 01/04/2024 Non-covered Recipient Entity
EMERSON CLINICAL RESEARCH INSTITUTE
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1100698353